{"url":"https://lda.senate.gov/api/v1/filings/8a2e3b37-9980-400f-ae62-e5ee12fb90da/","filing_uuid":"8a2e3b37-9980-400f-ae62-e5ee12fb90da","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2023,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/8a2e3b37-9980-400f-ae62-e5ee12fb90da/print/","filing_document_content_type":"text/html","income":null,"expenses":"500000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Beth Anne Cole","dt_posted":"2023-07-19T15:42:19-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"601 New Jersey Ave NW","registrant_address_2":"Suite 850","registrant_different_address":true,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":16032,"url":"https://lda.senate.gov/api/v1/registrants/16032/","house_registrant_id":31463,"name":"ASSOCIATION FOR ACCESSIBLE MEDICINES","description":"Association representing the interests of the generic pharmaceutical industry.","address_1":"601 New Jersey Ave NW","address_2":"Suite 850","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MARK RATNER","contact_telephone":"+1 202-249-7100","dt_updated":"2026-07-29T08:15:25.555128-04:00"},"client":{"id":121533,"url":"https://lda.senate.gov/api/v1/clients/121533/","client_id":12,"name":"ASSOCIATION FOR ACCESSIBLE MEDICINES","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2017-01-01"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Prescription Drug Costs. Drug Pricing. Civil Monetary Penalties. 180-Day Exclusivity. S.1114: Expanding Access to Low-Cost Generics Act of 2023. S.1128: Ensuring Access to Generic Medications Act. S.2129: Ensuring Access to Lower-Cost Medicines for Seniors Act. S.574: Increasing Prescription Drug Competition Act. Crenshaw Interchangeability and Bioequivalence Common Rating. H.R.1790: Biologics Competition Act of 2023. Labeling of Generic Drugs and Biosimilars. Hickenlooper Safe Harbor for Skinny Labeling. Generic Carveouts Patent Protected Information in Drug Labels Including Issues Related to GSK v. Teva. S.775: Increasing Transparency in Generic Drug Applications Act. Incentivize Domestic Manufacturing. Drug Shortages. Stockpile of Generic Drugs. GAO Report on Generic Drug Framework. Generic Drug User Fee Amendments (GDUFA). GDUFA III Negotiations. BsUFA III Negotiations. Biosimilars Insulin. Cost Sharing for Biosimilars. Same Strength Requirement for Biosimilars. Biosimilar Red Tape Eliminations Act. Expediting Competitive Biosimilar Competition. Crenshaw Competitive Biosimilar Therapy Bill. FDA Inspections. Shaheen-Sanders Inspections. Energy & Commerce Factory Inspection Legislation. FDA-PTO Collaboration. FDA Catalyst Decision. FDA Proposal on Combination Products. Shaheen-Cassidy Citizen Petition Legislation. Buy American Proposals. Inflation Reduction Act (IRA) Implementation. HELP Committee Briefing. H.R.3561: PATIENT Act of 2023. Trusted Partners in Medical Supply Chains.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":66451,"prefix":null,"prefix_display":null,"first_name":"CRAIG","nickname":null,"middle_name":null,"last_name":"BURTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70517,"prefix":null,"prefix_display":null,"first_name":"KARIN","nickname":null,"middle_name":null,"last_name":"HESSLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142070,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"KELBEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73046,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"RAAB","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":198,"name":"Natl Economic Council (NEC)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicare Part D Reform. Medicare Part D Program and Generic Drugs. Medicare Part D Low Income Subsidy (LIS) Program. Medicare Part D Coverage Gap Discount Program. Medicare Part D Tiering. S.2129: Ensuring Access to Lower-Cost Medicines for Seniors Act. Medicare Reimbursement for Biosimilars. Medicaid Rebate Penalty. Rebates and Pharmacy Benefit Managers (PBMs). Medicare Price Negotiation. Medicare Advantage Proposed Rule. Inflation Reduction Act (IRA) Implementation.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":66451,"prefix":null,"prefix_display":null,"first_name":"CRAIG","nickname":null,"middle_name":null,"last_name":"BURTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70517,"prefix":null,"prefix_display":null,"first_name":"KARIN","nickname":null,"middle_name":null,"last_name":"HESSLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142070,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"KELBEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73046,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"RAAB","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":198,"name":"Natl Economic Council (NEC)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"Patent Settlements. Patent Abuse. Terminal Disclaimers/Obviousness-Type Double Patenting. Skinny Labeling. Hickenlooper Safe Harbor for Skinny Labeling. Inter Partes Review. Impact of IPR decisions on 30-month stay. IPR Amendments. Cornyn-Leahy IPR Proposals. Enhancing Quality of Patents through the PTAB. Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. Patent Listings in Orange Book. H.R.1717/S.79: Interagency Patent Coordination and Improvement Act of 2023. S.142: Preserve Access to Affordable Generics and Biosimilars Act. S.148: Stop STALLING Act. S.150: Affordable Prescriptions for Patients Act of 2023. S.2140: A bill to amend title 35, United States Code, to address matters relating to patent subject matter eligibility, and for other purposes.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70517,"prefix":null,"prefix_display":null,"first_name":"KARIN","nickname":null,"middle_name":null,"last_name":"HESSLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142070,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"KELBEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73046,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"RAAB","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"FDA Funding.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70517,"prefix":null,"prefix_display":null,"first_name":"KARIN","nickname":null,"middle_name":null,"last_name":"HESSLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142070,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"KELBEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73046,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"RAAB","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"General Trade Issues. Drug Supply Chain. AAM Blueprint to Enhance the Security of the U.S. Supply Chain. Trusted Partners in Medical Supply Chains.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70517,"prefix":null,"prefix_display":null,"first_name":"KARIN","nickname":null,"middle_name":null,"last_name":"HESSLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73046,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"RAAB","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":198,"name":"Natl Economic Council (NEC)"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}